Trials Sponsors Conditions Drugs Pricing

Conditions

Chemical and Drug Induced Liver Injury

Keywords

Hepatotoxicity of Antituberculosis TherapyDILI

Outcome Measures

Primary Outcomes (1)

Proportion of DILI in antituberculosis therapy
The study primalily aims to observe the proportion of DILI in antituberculosis therapy,by monitoring and following up the liver function of the participants.
12 months(DILI occurs) or 24 months(None-DILI occur) after treatment initiation

Secondary Outcomes (1)

Proportion of liver injury of based liver disase,liver failure and adjustment of chemotherapy
12 months(DILI occurs) or 24 months(None-DILI occur) after treatment initiation

Interventions

None intervetionOther

None intervetion

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 85 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Patients who are about to start anti-tuberculosis treatment in the real world, including combined with different kinds of based disease, such as viral hepatitis,systematic infection,etc.

You may qualify if:

\) Patients who are about to start anti-tuberculosis treatment 2) Male or female, age \> 18 years old 3) Voluntary signing of "Subject Informed Consent Form"

Sponsors & Collaborators

Huashan Hospital
Otherlead

Biospecimen

Retention: NONE RETAINED

Blood

MeSH Terms

Conditions

Chemical and Drug Induced Liver Injury

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System DiseasesDrug-Related Side Effects and Adverse ReactionsChemically-Induced DisordersPoisoning

Study Officials

Wenhong Zhang
Huashan Hospital
STUDY CHAIR
Yongguo LI
First Affiliated Hospital of Harbin Medical University
PRINCIPAL INVESTIGATOR
Dapeng Bai
Haihe Hospital in Tianjin
PRINCIPAL INVESTIGATOR
Meiying Wu
The Fifth Hospital in Suzhou
PRINCIPAL INVESTIGATOR

Central Study Contacts

Wenhong Zhang

CONTACT

13801844344 zhangwenhong@fudan.edu.cn

Taoping Weng

CONTACT

18817583793

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Target Duration: 1 Year
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Director of Division of Infectious Diseases

Study Record Dates

First Submitted

November 7, 2019

First Posted

November 12, 2019

Study Start

December 5, 2019

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

Hepatotoxicity of Antituberculosis Therapy (HAT) Study

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record